Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Marketwired
270 Leser
Artikel bewerten:
(0)

Prism Medical Reports First Quarter Results

Finanznachrichten News

TORONTO, ONTARIO -- (Marketwired) -- 04/28/15 -- Prism Medical Ltd., ("Prism Medical" or "the Company") (TSX VENTURE: PM), a leading provider of durable medical equipment and related services to the mobility challenged, today reported financial results for the first quarter (Q1) ended February 28, 2015.

FINANCIAL HIGHLIGHTS

Three months ended February 28
----------------------------------------------------------------------------
                                                  2015               2014(i)
                                                     $                     $
----------------------------------------------------------------------------
Revenues                                        12,181                 9,890
Gross margin                                     4,868                 4,266
  (as % of revenues)                             40.0%                 43.1%

Net income (loss) from
 operations                                        402                 (179)
  (as % of revenues)                              3.3%                 -1.8%

Net income from discontinued
 operations                                          -                   847

Net Income                                         402                   668

Adjusted EBITDA
  Continuing operations                          1,423                   525
  (as % of revenues)                             11.7%                  5.3%

Pro-forma Adjusted EBITDA                        1,519                   525

Basic earnings per share
From continuing operations                        0.08                (0.02)
From discontinued operations                         -                  0.10
From net income (loss)                            0.08                  0.08
Diluted earnings per share
From continuing operations                        0.08                (0.02)
From discontinued operations                         -                  0.10
From net income (loss)                            0.08                  0.08

----------------------------------------------------------------------------
----------------------------------------------------------------------------

                                                       As at           As at
                                                February 28,     November 30
                                                        2015            2014
                                                           $               $
----------------------------------------------------------------------------
Total assets                                          53,414          46,491
Total liabilities                                     24,375          20,009
Cash and cash equivalents                              4,608           6,497
Bank indebtedness                                      2,487           1,160
Current portion of long-term debt                      2,205           1,976
Long-term debt                                        11,111           8,040
Shareholders' equity                                  29,039          26,482
Common shares (in thousands)                           4,827           4,742
----------------------------------------------------------------------------
----------------------------------------------------------------------------

(i)Restated to reflect continuing operations

First Quarter Highlights

--  Strong year-over-year growth in revenue for the quarter, with revenues
    increasing by 23% from $9.9 million in Q1 2014 to $12.2M in Q1 2015
--  Adjusted EBITDA from continuing operation of $1.4 million, significantly
    higher than $0.5 million earned in Q1 2014
--  First quarter 2015 net income from continuing operations was $402
    thousand or $0.08 per common share compared to a loss of $179 thousand
    from continuing operations in the first quarter of 2014 or $0.02 per
    common share
--  Completion of the acquisition of the assets and the business of Angel
    Accessibility Solutions Limited, a leading provider of durable medical
    equipment and related services to the mobility challenged. As part of
    the transaction, the Company acquired the exclusive Canadian rights,
    other than for Quebec and Atlantic provinces, to distribute and service
    bathing, transfer and transport devices and hygiene products on behalf
    of Beka-Hospitec
--  For a comprehensive discussion of the quarter please refer to the
    Company's Management Discussion and Analysis and Financial Statements
    for the three month period ended February 28, 2015. Both these documents
    can be found on SEDAR or the Company's website

Chairman's Comments

"We remain committed to growing the North American business both organically and from acquisitions. As the US market continues to mature we anticipate continued growth in revenues, gross profit and shareholder return. In addition to the approval of a quarterly dividend payment of $0.125 per common share, with the positive first quarter results and a continued positive future outlook, the Board of Directors has declared a special dividend of $1.00 per share, in effect returning capital to shareholders which is not required to fund operations. Both dividends are to be paid on June 5, 2015 to shareholders of record on May 15, 2015."

Outlook

The Company intends to grow sales and profitability and provide a reasonable return on shareholders' equity with a focus on the North American market. The Company believes that performance will be positively affected by a continued North American institutional and homecare demand for our products, improved manufacturing efficiencies, greater geographic coverage, and revenues and profits from new product introductions. During the past year the Company's North American operations have materially improved. Management believes that there are significant growth opportunities within the expanding North American health care industry both through organic growth and acquisitions that offer the potential to significantly increase shareholder value, while remaining consistent with Prism Medical's key growth strategies of vertical integration, product diversification and the application of relevant knowledge by its service oriented personnel.

The demand for our core products and services, in management's estimation, continues to experience growth at different rates in the geographic markets in which we participate. Government funding for our products in Canada is a key driver of sales. Although government policies related to healthcare in the markets we operate continues to change, we believe that the long term trend continues to be favorable.

Management believes that the US market holds the greatest long-term potential to provide above-average revenue growth both in the institutional and homecare markets. While budget constraints and the cyclicality of the institutional order pipeline can cause variability in US revenue, our efforts to build a larger footprint in this market have already translated into strong revenue growth.

Dividend

On April 28, 2015, the Board of Directors approved the payment of a dividend of $0.125 per common share and a special dividend of $1.00 per common share to shareholders of record on May 15, 2015 to be paid on June 5, 2015.

About Prism Medical Ltd.

Prism Medical is a vertically integrated manufacturer and leading provider of equipment and services used to move and handle mobility challenged individuals in a safe and dignified manner. Prism Medical's products are marketed under the brand names of Prism Medical, ErgoSafe, Waverly Glen and Nightingale in the homecare, acute care and long-term care markets throughout North America. The Company offers solutions that encourage improved care, quality of life and mobility, while seeking to lower the overall cost of the caregiving function in a number of ways, including reducing the incidence of handling-related injuries among caregivers. In addition, the Company through its network of Nightingale dealers provides an integrated suite of products and services that make home care a viable option for many people. For further information visit Prism Medical's website at www.prismmedicalltd.com or www.sedar.com.

Non-IFRS Financial Measures

Prism Medical's consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS). The Company also uses non-IFRS measures such as Adjusted EBITDA to measure its financial performance. Adjusted EBITDA from continuing operations consists of earnings before interest, income taxes, depreciation, amortization, stock-based compensation. Adjusted EBITDA from continuing operations is a financial metric used by many investors to compare companies on the basis of operating results, asset value and the ability to incur and service debt. Management believes that Adjusted EBITDA from continuing operations is a useful measure for evaluating the performance of the Company. Adjusted EBITDA from continuing operations is not a recognized measure under IFRS and does not have a standardized meaning prescribed by IFRS and may not be comparable to similarly titled financial metrics reported by other companies.

Forward-Looking Information

This document contains forward-looking statements relating to our operations and to the environment in which we operate and our strategy, action plans and investments, which may involve estimates, forecasts and projections. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict and/or are beyond our control. A number of important factors could cause actual outcomes and results to differ materially from those expressed in these forward-looking statements. These factors include those set forth in this report and our other public filings. Consequently, readers should not place any undue reliance on such forward-looking statements. These forward-looking statements are made as of the date of this report. Prism Medical is under no obligation to update any forward-looking statements contained herein should material facts change due to new information, future events or other factors. All forward-looking statements attributable to Prism Medical are expressly qualified by these cautionary statements.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contacts:
Prism Medical Ltd.
Andy McIntyre
Chairman and Chief Executive Officer
416-260-2145 ext. 235
amcintyre@prismmedicalinc.com

© 2015 Marketwired
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.